Clinical Trials Logo

Clinical Trial Summary

Despite longer life expectancies due to combination antiretroviral therapy (cART), the prevalence of HIV-associated neurocognitive disorders (HAND) persists thus affecting 52% of the HIV population. Poor sleep quality is commonly reported in older adults and has been related to neurocognitive impairments. This is concerning given studies have shown that up to 75% of adults with HIV experience poor sleep, and by 2020, 70% of adults with HIV will be age 50 and older. It is important to examine sleep quality as it relates to neurocognitive function and HAND in older adults with HIV given its negative impact on cART adherence. Compared to Whites with HIV, African Americans (AA) are disproportionately affected by HIV and are more likely to experience poor sleep quality. This primary goal of this 1-year cross-sectional study is to examine racial differences in sleep quality and neurocognitive function among 60 African Americans and Whites with HIV (age 50+).


Clinical Trial Description

This study is designed with two aims: Aim 1a: To explore differences in sleep health between older HIV+ AA and Whites. 1b: To explore differences in domain-specific neurocognitive impairments between older HIV+ AA and Whites. Aim 2a: To explore the relationship between sleep health and neurocognitive function. 2b: To explore the relationship between sleep health and cART adherence. 2c: To explore mediation effects of cART adherence between sleep health and neurocognitive function. This is the first study to explore racial disparities in sleep health and neurocognitive function, using EEG/ERP metrics, among older HIV+ adults. There are two phases in this study: Phase I which consists of neurocognitive testing and sleep assessments with actigraphy, and Phase II which consist of a 20-30 min EEG. Measurements of electrical brain activity will be captured while participants engage in an Attention Network Test which measures executive function, attention, and speed of processing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04015830
Study type Interventional
Source University of Alabama, Tuscaloosa
Contact Shameka L Cody, PhD
Phone 2053483374
Email slcody@ua.edu
Status Not yet recruiting
Phase N/A
Start date August 1, 2019
Completion date June 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT01263938 - Modulation of Monocyte Activation by Atorvastatin in HIV Infection Phase 4
Recruiting NCT01599975 - A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV Phase 3
Recruiting NCT05586581 - SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy Phase 1/Phase 2
Recruiting NCT05571761 - Teleneuropsychological Intervention in Asymptomatic HIV Seropositive Patients: N&C NeuroChange N/A
Completed NCT01665846 - Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders Phase 1
Completed NCT01600170 - Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND) Phase 4
Terminated NCT03081117 - Intranasal Insulin for the Treatment of HAND Phase 1/Phase 2